Amonafide

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.^[1][2]

Amonafide

Clinical data
Trade names	Xanafide, Quinamed
ATC code	none
Identifiers
IUPAC name 5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
CAS Number	69408-81-7
PubChem CID	50515
ChemSpider	45804 Y
UNII	1Q8D39N37L
KEGG	D10090 Y
ChEMBL	ChEMBL428676 Y
CompTox Dashboard (EPA)	DTXSID30219562
Chemical and physical data
Formula	C16H17N3O3
Molar mass	299.330 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 Y Key:UPALIKSFLSVKIS-UHFFFAOYSA-N Y
(verify)

It was being developed as an anti-cancer therapy by Antisoma.^[3]

As of 2008^[update], it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).^[4] In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.^{[citation needed]}

See also

• Alrestatin